123 related articles for article (PubMed ID: 32691711)
1. Molecular Dynamics in Esophageal Adenocarcinoma: Who's in Control?
Dang T; Chai J
Curr Cancer Drug Targets; 2020; 20(10):789-801. PubMed ID: 32691711
[TBL] [Abstract][Full Text] [Related]
2. CCN1 sensitizes esophageal cancer cells to TRAIL-mediated apoptosis.
Dang T; Modak C; Meng X; Wu J; Narvaez R; Chai J
Exp Cell Res; 2017 Dec; 361(1):163-169. PubMed ID: 29055676
[TBL] [Abstract][Full Text] [Related]
3. TNF antagonizes CCN1 in apoptosis in esophageal adenocarcinoma.
Dang T; Chang Z; Meng J; Cui X; Wang P; Chai J
Cytokine; 2022 Jan; 149():155728. PubMed ID: 34634651
[TBL] [Abstract][Full Text] [Related]
4. Acid/bile exposure triggers TRAIL-mediated apoptosis in esophageal cancer cells by suppressing the decoy receptors and c-FLIP
Meng X; Chang Z; Che N; Wu J; Dang T; Chai J
Int J Biochem Cell Biol; 2020 May; 122():105736. PubMed ID: 32135301
[TBL] [Abstract][Full Text] [Related]
5. CCN1 is critical for acid-induced esophageal epithelial cell transformation.
Modak C; Mouazzen W; Narvaez R; Reavis KM; Chai J
Biochem Biophys Res Commun; 2010 Feb; 392(4):533-7. PubMed ID: 20097175
[TBL] [Abstract][Full Text] [Related]
6. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
[TBL] [Abstract][Full Text] [Related]
7. The Role of CCN1 in Esophageal Adenocarcinoma: What We Have Learned From the Lab.
Chang Z; Dang T; Meng X; Chai J
Cancer Control; 2022; 29():10732748221074734. PubMed ID: 35291889
[No Abstract] [Full Text] [Related]
8. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.
Lin L; Bass AJ; Lockwood WW; Wang Z; Silvers AL; Thomas DG; Chang AC; Lin J; Orringer MB; Li W; Glover TW; Giordano TJ; Lam WL; Meyerson M; Beer DG
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4251-6. PubMed ID: 22375031
[TBL] [Abstract][Full Text] [Related]
9. Loss of glutathione peroxidase 7 promotes TNF-α-induced NF-κB activation in Barrett's carcinogenesis.
Peng DF; Hu TL; Soutto M; Belkhiri A; El-Rifai W
Carcinogenesis; 2014 Jul; 35(7):1620-8. PubMed ID: 24692067
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma.
Popnikolov NK; Gatalica Z; Adegboyega PA; Norris BA; Pasricha PJ
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):161-5. PubMed ID: 16785783
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling.
Rasheduzzaman M; Jeong JK; Park SY
Life Sci; 2018 Sep; 208():208-220. PubMed ID: 30031063
[TBL] [Abstract][Full Text] [Related]
12. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.
Sheikh MS; Huang Y; Fernandez-Salas EA; El-Deiry WS; Friess H; Amundson S; Yin J; Meltzer SJ; Holbrook NJ; Fornace AJ
Oncogene; 1999 Jul; 18(28):4153-9. PubMed ID: 10435597
[TBL] [Abstract][Full Text] [Related]
13. Esophageal cancer cells convert the death signal from TRAIL into a stimulus for survival during acid/bile exposure.
Chang Z; Dang T; Che N; Yu H; Chai J; Chen W
Dig Liver Dis; 2020 Oct; 52(10):1195-1200. PubMed ID: 32505571
[TBL] [Abstract][Full Text] [Related]
14. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage.
Zhou Z; Lu H; Zhu S; Gomaa A; Chen Z; Yan J; Washington K; El-Rifai W; Dang C; Peng D
J Exp Clin Cancer Res; 2019 Jan; 38(1):13. PubMed ID: 30626422
[TBL] [Abstract][Full Text] [Related]
15. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
Renouf DJ; Zhai R; Sun B; Xu W; Cheung WY; Heist RS; Kulke MH; Cescon D; Asomaning K; Marshall AL; Li S; Christiani DC; Liu G
J Gastroenterol Hepatol; 2013 Sep; 28(9):1482-8. PubMed ID: 23735059
[TBL] [Abstract][Full Text] [Related]
16. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma.
Sethi N; Kikuchi O; McFarland J; Zhang Y; Chung M; Kafker N; Islam M; Lampson B; Chakraborty A; Kaelin WG; Bass AJ
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391338
[TBL] [Abstract][Full Text] [Related]
18. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
[TBL] [Abstract][Full Text] [Related]
19. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
20. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.
Figueroa JD; Terry MB; Gammon MD; Vaughan TL; Risch HA; Zhang FF; Kleiner DE; Bennett WP; Howe CL; Dubrow R; Mayne ST; Fraumeni JF; Chow WH
Cancer Causes Control; 2009 Apr; 20(3):361-8. PubMed ID: 18989634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
